Houston-based EndoQuest in October 2025 announced plans to integrate Nvidia’s IGX Thor platform into its next-generation surgical robotic system.
Nvidia designed IGX Thor for more computing power, better energy efficiency and awareness compared to previous platforms. The cloud computing giant has entered several collaborations on surgical robotics, including with CMR Surgical, Johnson & Johnson MedTech, Karl Storz’s Asensus, Moon Surgical, Virtual Incision, Neptune Surgical and Stereotaxis.
EndoQuest’s collaboration focuses on its visualization system, robotic control and secure cloud services. It aims to deliver real-time image processing, robotic control, and cloud-enabled intelligence in a unified architecture.
The company plans to build its next-generation platform as a suite of real-time, image-based solutions. It hopes to support intraoperative tissue differentiation, perfusion visualization, and the execution of select autonomous surgical tasks. The company plans to complement this with advanced capabilities for remote robotic operation, teleproctoring for surgical guidance and collaborative surgical workflows.
As part of the initiative, EndoQuest plans to leverage Nvidia AI infrastructure. It plans to tap into low-latency sensor processing and 3D visualization, precise and time-synchronized motion control and secure cloud connectivity. The capabilities would support fleet management, data services, teleproctoring and future AI deployment.
This effort coincides with EndoQuest’s PARADIGM trial evaluating its endoluminal surgical robot. PARADIGM looks at the system in lower gastrointestinal tract procedures.
More about the company’s endoluminal surgical robot
EndoQuest develops its Endoluminal Surgical (ELS) system. It designed the surgical robot platform to address unmet needs in GI and other endoluminal surgeries. The system can deliver precision and flexibility to improve patient outcomes. The company says it enables endoluminal procedures with the visualization, precision and main tenets of conventional surgical techniques. It allows for surgical tasks and maneuvers not currently possible in advanced therapeutic endoscopy.
The proprietary technology navigates and performs procedures within the body’s lumina spaces, allowing for minimally invasive interventions. It makes it possible for therapeutic endoscopists and surgeons to operate through a trans-oral or trans-anal approach.
The FDA granted investigational device exemption (IDE) for the system in December 2024. In May 2025, the company announced the first colorectal cases in the trial, then reported its first gastroenterologist-performed case in October 2025.
Commentary from EndoQuest Robotics officials
Dr. Todd Wilson, chief medical officer and chair of the international advisory board of EndoQuest Robotics, said:
“AI and robotics will redefine the operating room by enhancing surgical vision and precision beyond human limits. This shift will enable earlier diagnosis and highly targeted therapies that minimize patient impact while maximizing the potential for cure.”
Eduardo Fonseca, EndoQuest CEO, said:
“By powering our visualization, control, and secure cloud services with NVIDIA AI infrastructure, we aim to streamline our system architecture for performance, reliability and clinical scalability. This unified architecture is critical to advancing our technology for endoluminal robotic surgery and supporting future capabilities in imaging intelligence, robotic performance, and connected surgical workflows.”
